Announcements Trials
Browse Landscape

Status

Completed 221Recruiting 152Unknown 129Terminated 94Active not recruiting 49Not yet recruiting 48Withdrawn 32Enrolling by invitation 8Suspended 4No longer available 2Available 2Approved for marketing 2

Sponsor Class

INDUSTRY 2

Study Type

Expanded_access 2

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Head & Neck 1Gynecologic 1Genitourinary 1Dermatologic 1CNS 1

Conditions

Pancreatic Neoplasms 6Ovarian Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Stomach Neoplasms 3Sarcoma 3Prostatic Neoplasms 3Melanoma 2Head and Neck Neoplasms 2Glioblastoma 2Gastrointestinal Neoplasms 2Colorectal Neoplasms 2Cholangiocarcinoma 2Carcinoma, Squamous Cell 2Carcinoma, Hepatocellular 2Breast Neoplasms 2Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Recurrence 1Pancreatic Ductal Adenocarcinoma (PDAC) 1Osteosarcoma 1Neurofibrosarcoma 1Neuroblastoma 1Neoplasms 1Lymphoma, Non-Hodgkin 1Hodgkin Disease 1Hepatoblastoma 1Hearing Loss 1Gastrointestinal Stromal Tumors 1Esophageal Neoplasms 1Endometrial Neoplasms 1

Interventions

ulixertinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Available × Cholangiocarcinoma × Gastrointestinal × Clear all
NCT04566393 2026-06-04

Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies

xCures

Available
CNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Glioblastoma, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT06370013 2024-04-17

Rollover Study to Provide Continued Access to TT-00420 (Tinengotinib) for Subjects With Advanced Solid Tumors

TransThera Sciences (Nanjing), Inc.

Available
Gastrointestinal

Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡